Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines

Globalization and Health

Volumn 7, Issue , 2011, Pages

  Mackintosh, Maureen ^a   Chaudhuri, Sudip ^b   Mujinja, Phares G M ^c  

^a OPEN UNIVERSITY   (United Kingdom)

^b INDIAN INSTITUTE OF MANAGEMENT CALCUTTA   (India)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RESISTANCE; ECONOMIC ANALYSIS; HEALTH POLICY; MANUFACTURING; MARKET SYSTEM; MEDICINE; NONGOVERNMENTAL ORGANIZATION; STATE ROLE;

ARTICLE; COMMERCIAL PHENOMENA; DRUG CONTROL; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; EUROPE; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; INDIA; NON GOVERNMENTAL ORGANIZATION; PRIORITY JOURNAL; QUALITY CONTROL; SOCIAL MARKETING; TANZANIA; WHOLESALING;

EUROPE; INDIA; TANZANIA;

EID: 79952045584     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-7-4     Document Type: Article

References (43)

1. World Health Organisation (WHO) The World Medicines Situation 2004, Geneva: WHO, World Health Organisation (WHO).
2. Chaudhuri S. The WTO and India's Pharmaceutical Industry: Patent Protection, TRIPS, and Developing Countries 2005, New Delhi: Oxford University Press.
3. Chaudhuri S. The gap between successful innovation and access to its benefits: Indian pharmaceuticals. European Journal of Development Research 2007, 19(1):49-65.
4. LOCOST/JSS Impoverishing the Poor: Pharmaceuticals and Drug Pricing in India 2004, LOCOST and Jan Swasthya Sahyog, Vadodara and Bilaspur, LOCOST/JSS.
5. World Health Organisation (WHO) Equitable access to essential medicines: a framework for collective action. WHO Policy Perspectives on Medicines 8 2004, Geneva: WHO, World Health Organisation (WHO).
6. Mackintosh M, Mujinja PGM. Markets and policy challenges in access to essential medicines for endemic disease. Journal of African Economies 2010, 19(AERC Supp. 3):iii166-iii200.
7. Mossialos E, Mrazek M. Entrepreneurial behaviour in pharmaceutical markets and the effects of regulation. Regulating Entrepreneurial Behaviour in European Health Systems 2002, Buckingham: Open University Press, Saltman R, Busse R, Mossialos E.
8. Chaudhury RR, Gurbani NK. Enhancing Access to Quality Medicines for the Underserved 2004, New Delhi, Anamaya Publishers.
9. Lalitha N. Tamil Nadu Government Intervention and Prices of Medicines. Economic & Political Weekly 2008,
10. Turshen M. Reprivatizing pharmaceutical supplies in Africa. Journal of Public Health Policy 1999, 22(2):198-225.
11. Mujinja P, Mpembeni R, Lake S. Regulating private drug outlets in Dar es Salaam: perceptions of key stakeholders. The New Private Public Mix in Health: Exploring Changing Landscapes 2003, Global Forum for Health Research, Geneva, Söderlund N, Mendosa-Arana P, Goudge P.
12. Ravishankar N, Gubbins P, Cooley RJ, Leach-Kemon K, Michaud CM, Jamison DT, Murray CJL. Financing of global health: tracking development assistance for health from 1990 to 2007. The Lancet 2009, 373:2113-2124.
13. Médicins sans Frontières (MSF) Untangling the Web of Antiretroviral Price Reductions 2010, Geneva: MSF, Médicins sans Frontières (MSF)., http://www.msfaccess.org/resources/key-publications/
14. Koivusalo M, Mackintosh M. Commercial influence and global nongovernmental public action in health and pharmaceutical policies. International Journal of Health Services
15. All India Drug Action Network (AIDAN). , http://aidanindia.wordpress.com
16. Arrow KJ. Uncertainty and the welfare economics of medical care. American Economic Review 1963, LIII(5):941-973.
17. Hansmann H. Economic theories of nonprofit organization. The Nonprofit Sector: a Research Handbook 1987, New Haven: Yale University Press, Powell WW.
18. Valentinov V. The economics of the non-distribution constraint: a critical reappraisal. Annals of Public and Cooperative Economics 2008, 79(1):35-52.
19. Besley T. Principled Agents? The political economy of good government 2006, Oxford University Press.
20. Grabowsi DC, Hirth R. Competitive spillovers across non-profit and for-profit nursing homes. Journal of Health Economics 2003, 22:1-22. 10.1016/S0167-6296(02)00093-0, 12564715.
21. Brhlikova P. Models of competition between one for-profit and one non-profit firm. CERGE-EI Working Paper series No 240 2006, Prague: Charles University.
22. O'Donnell O, van Doorslaer E, . 23 others Who pays for health care in Asia?. EQUITAP Project Working Paper No 1 2005, 23 others., http://www.equitap.org
23. Mackintosh M, Tibandebage P. Inclusion by design: rethinking regulatory intervention in Tanzanian health care. Journal of Development Studies 2002, 39(1):1-20.
24. Baldwin R, Scott C, Hood C. Introduction. A Reader on Regulation 1998, Oxford: Oxford University Press, Baldwin R, Scott C, Hood C.
25. Braithwaite J, Drahos P. Global Business Regulation 2000, 550ff. Cambridge: Cambridge University Press.
26. Frydman RCW, Gray A, Rapaczynski A, . (eds) Corporate Governance in Central and Eastern Europe 1996, Budapest: CEU Press, (eds).
27. Deakin R, Michie J, . (eds) Contracts and Competition. Cambridge Journal of Economics 1997, 21(2):121-302. (eds).
28. Mackintosh M. Informal regulation: a conceptual framework and application to decentralised mixed health care systems. Economic Decentralisation and Public Management Reform 1999, Cheltenham: Edward Elgar, Mackintosh M, Roy R.
29. The Nonprofit Sector: A Research Handbook 1987, New Haven: Yale University Press, Powell W.
30. Anheier H, Ben-Ner A, . (eds) The Study of Nonprofit Enterprise: Theories and Approaches 2003, New York: Kluwer Academic, (eds).
31. Defourny J. Introduction: from the third sector to social enterprise. The Emergence of Social Enterprise 2001, London, Routledge, Borzaga C, Defourny J.
32. Peredo AM, Mclean M. Social entrepreneurship: a critical review of the concept. Journal of World Business 2006, 41:6-65.
33. Kerlin JA. Social enterprise in the United States and Europe: understanding and learning from the differences. Voluntas 2006, 17:247-263.
34. World Health Organisation (WHO)/Ecumenical Pharmaceutical Network (EPN) Multi-Country Study of Medicines Supply and Distribution Activities of Faith-Based Organizations in Sub-Saharan African Countries 2006, Geneva: WHO, World Health Organisation (WHO)/Ecumenical Pharmaceutical Network (EPN)., http://www.who.int/medicines/areas/access/EN_EPNstudy.pdf
35. Chaudhuri S, Mackintosh M, Mujinja PGM. Indian generics producers, access to essential medicines and local production in Africa: an argument with reference to Tanzania. European Journal of Development Research 2010, 22(4):451-468.
36. CDMU CDMU., http://www.cdmubengal.org
37. World Health Organisation (WHO) Prequalification Programme. World Health Organisation (WHO)., http://apps.who.int/prequal/
38. ORG-MARG Retail Store Audit For Pharmaceutical Products in India. 2002, Baroda: AC Nielson ORG-MARG Pvt Ltd, ORG-MARG.
39. CIMS CIMS: Updated Prescribers' Handbook 2003, Bangalore: Medimedia Health Pvt Ltd, January - Update 1, CIMS.
40. Mathew JC. LOCOST markets essential drugs at a fraction of top branded products. Pharmabiz 2006,
41. Gilson L. Trust and the development of health care as a social institution. Social Science and Medicine 2003, 53:1457-1468.
42. Leonard KL. When both states and markets fail: asymmetric information and the role of NGOs in African health care. International Review of Law and Economics 2002, 22(1):61-80.
43. ORG-IMS Stockist Secondary Audit. ORG-IMS., http://www.orgims.co.in/